International Clinical Trial: An Open Label, Randomized, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Dapagliflozin 10 mg Tablet versus FORXIGA Dapagliflozin 10 mg Tablet in Healthy Human Volunteers under Fasting Conditions

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (TCTR20260415002) titled 'An Open Label, Randomized, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Dapagliflozin 10 mg Tablet versus FORXIGA Dapagliflozin 10 mg Tablet in Healthy Human Volunteers under Fasting Conditions' on April 15.

Study Type: Interventional

Study Design: Randomized

Primary Sponsor: International Bio Service Co., Ltd.

Condition: Bioequivalence study in healthy Thai volunteers Dapagliflozin, Bioequivalence study, Healthy Dapagliflozin, Bioequivalence study, Healthy

Intervention: Each tablet contains dapagliflozin 10 mg.,Each film-coated tablet contains 10 mg dapagliflozin as d...